• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cantor Fitzgerald reiterated coverage on HEXO with a new price target

    12/15/21 4:39:56 AM ET
    $HEXO
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $HEXO alert in real time by email
    Cantor Fitzgerald reiterated coverage of HEXO with a rating of Neutral and set a new price target of $1.20 from $2.10 previously
    Get the next $HEXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HEXO

    DatePrice TargetRatingAnalyst
    3/4/2022$1.00 → $1.25Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022Hold → Speculative Buy
    Canaccord Genuity
    3/4/2022$1.20 → $0.90Neutral
    Cantor Fitzgerald
    1/27/2022$1.07 → $0.53Underperform → Hold
    Jefferies
    12/15/2021$2.00 → $0.80Neutral → Underperformer
    CIBC
    12/15/2021Neutral → Sector Underperform
    CIBC
    12/15/2021$2.10 → $1.20Neutral
    Cantor Fitzgerald
    10/29/2021$2.29 → $2.10Neutral
    Cantor Fitzgerald
    More analyst ratings

    $HEXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HEXO Corp. Announces Completion of Acquisition by Way of Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today the closing of the second of two tranches of the non-brokered private placement of Series 1 Preferred Shares (the "Private Placement") previously announced on June 1, 2023 and the subsequent completion of the transactions contemplated by the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement") involving the Company and Tilray Brands, Inc. ("Tilray"). "On behalf of HEXO's board and management team, I'd like to extend our deepest thanks to the entire HEXO team for their continued commitment to our business and customers," said Charlie Bow

      6/22/23 5:02:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Corp. Announces Receipt of Final Order for Arrangement With Tilray Brands, Inc.

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company") announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted the final order (the "Final Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Arrangement"), pursuant to which Tilray Brands, Inc. ("Tilray") will acquire all of the issued and outstanding common shares (the "Common Shares") and non-voting Series 1 Preferred Shares of the Company. Holders of Common Shares of the Company (the "Common Shareholders") will receive 0.4352 of a share of Tilray common stock (the "Tilray Shares") for each w

      6/19/23 4:06:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care
    • HEXO Reports Q3'23 Financial Results

      HEXO Corp. (TSX:HEXO, NASDAQ:HEXO) ("HEXO" or the "Company"), a leading producer of high-quality cannabis products, today reported its financial results for the third quarter of the 2023 fiscal year ("Q3'23"). All currency amounts are stated in Canadian dollars unless otherwise noted. "In the third quarter, we entered into a definitive arrangement agreement whereby Tilray will acquire all outstanding shares of HEXO," said Charlie Bowman, President and Chief Executive Officer of HEXO. "We continue to expect the transaction will be completed by June 30, 2023." "HEXO recorded $21.6 million in net revenues in the third quarter, representing an 11% decline from the second quarter," noted Jul

      6/14/23 4:51:00 PM ET
      $HEXO
      Pharmaceuticals and Biotechnology
      Health Care